LSTA
HEALTHCARELisata Therapeutics Inc
$3.26-0.01 (-0.31%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving LSTA Today?
No stock-specific AI insight has been generated for LSTA yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$1.81$5.07
$3.26
Fundamentals
Market Cap$30M
P/E Ratio—
EPS$-1.90
Dividend Yield—
Dividend / Share—
ROE-0.8%
Profit Margin—
Debt / Equity—
Trading
Volume44K
Avg Volume (10D)—
Shares Outstanding9.1M
LSTA News
20 articles- Lisata Therapeutics shares up 20% as Kuva Labs acquisition advancesProactive Investors·Mar 9, 2026
- Lisata Therapeutics Enters into Definitive Agreement to be Acquired by Kuva Labs, Inc.Yahoo Finance·Mar 6, 2026
- Lisata Therapeutics Announces Mutual Termination of License Agreement with Qilu Pharmaceutical for CertepetideYahoo Finance·Jan 27, 2026
- Lisata Therapeutics And 2 Other Penny Stocks Worth WatchingYahoo Finance·Jan 22, 2026
- How The Evolving Story For Lisata Therapeutics (LSTA) Is Reshaping Its Valuation OutlookYahoo Finance·Jan 22, 2026
- Lisata Therapeutics Enters Into Term Sheet to be Acquired by Kuva Labs for $4.00 Per Share in an All-Cash Tender OfferYahoo Finance·Jan 21, 2026
- LSTA Releases Valuations Report on Level 3 LoansYahoo Finance·Dec 4, 2025
- Lisata Therapeutics Inc (LSTA) Q3 2025 Earnings Call Highlights: Strategic Alliances and Cost ...Yahoo Finance·Nov 7, 2025
- Lisata Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business UpdateYahoo Finance·Nov 6, 2025
- Lisata Therapeutics Wins 2025 BioTech Breakthrough Award for ‘Overall BioPharma Solution of the Year’Yahoo Finance·Nov 6, 2025
- Lisata Therapeutics Highlights Positive Preclinical Data of Certepetide as Part of Antibody-Drug Conjugate Combinations as Reported by Licensing Partner CatalentYahoo Finance·Nov 4, 2025
- Lisata Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Business Update on Thursday, November 6, 2025Yahoo Finance·Oct 30, 2025
- Lisata Therapeutics to Present at LD Micro Main Event XIXYahoo Finance·Oct 13, 2025
- Lisata Therapeutics Partners with Catalent on ADC TechnologyYahoo Finance·Oct 9, 2025
- Lisata Therapeutics and Catalent Announce Global Antibody-Drug Conjugate (ADC) License AgreementYahoo Finance·Oct 8, 2025
- Is Lisata Therapeutics (NASDAQ:LSTA) In A Good Position To Invest In Growth?Yahoo Finance·Oct 3, 2025
- Lisata Therapeutics Highlights Preliminary Data in Pancreatic Cancer StudyYahoo Finance·Sep 30, 2025
- Lisata Therapeutics Announces Encouraging Preliminary Results from the Pancreatic Cancer Cohort of the CENDIFOX TrialYahoo Finance·Sep 29, 2025
- Lisata Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment ConferenceYahoo Finance·Sep 2, 2025
- LSTA Applauds Executive Order Increasing 401 (K) Access to Private Markets InvestmentsYahoo Finance·Aug 7, 2025
All 20 articles loaded
Price Data
Open$3.20
Previous Close$3.27
Day High$3.29
Day Low$3.20
52 Week High$5.07
52 Week Low$1.81
52-Week Range
$1.81$5.07
$3.26
Fundamentals
Market Cap$30M
P/E Ratio—
EPS$-1.90
Dividend Yield—
Dividend / Share—
ROE-0.8%
Profit Margin—
Debt / Equity—
Trading
Volume44K
Avg Volume (10D)—
Shares Outstanding9.1M
About Lisata Therapeutics Inc
Lisata Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on developing and commercializing cellular therapies to reverse disease and/or promote regeneration of damaged tissue. The company is headquartered in Basking Ridge, New Jersey.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—